Akebia Therapeutics (AKBA) Reports Q3 Net Loss of $59.5M, Cash and Cash Equivalents of $207.2M

Akebia Therapeutics (NASDAQ: AKBA) reported Q3 net loss of $59.5M. Revenue for the quarter came in at $48.8 million versus the consensus estimate of $49.67 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Evolution Petroleum to buy Midland Basin mineral rights for $16M
• Corporación América Airports S.A. (CAAP) Misses Q2 EPS by 18c